PR Newswire Clinical TrialsOriginal article
FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer
Trial StartCAR T-cellsPositive
AI Analysis
Summary
The FDA has cleared a clinical trial at University of Colorado Anschutz investigating engineered CAR T-cells that target two pathways to treat colorectal cancer. The trial will evaluate the investigational therapy's ability to combat tumors while overcoming immune evasion mechanisms.
Clinical Trial Data
Outcome Details
FDA granted permission for clinical trial using engineered CAR T-cells targeting two pathways in colorectal tumors
Importance:6/10
Sentiment:
0.60
CAR T-cell therapycolorectal cancerFDA clearanceclinical trialimmunotherapy
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 10, 2026 7:15 PM